followed by a prior history of the event and sex.In the decision model we included the following thirteen individual NSAIDs: aceclofenac, celecoxib, diclofenac, etoricoxib, ibuprofen, indometacin, ketoprofen, ketorolac, meloxicam, naproxen, nimesulide, piroxicam, and rofecoxib.In general, the 'preferred' drugs based on their GI and CV safety profile were aceclofenac and celecoxib, followed by nimesulide and ibuprofen.Two NSAIDs (piroxicam and ketorolac) consistently ranked lowest.Conclusion: The SOS consortium provided an integrated GI and CV safety decision model for new NSAID users, incorporating thirteen individual NSAIDs, which may aid physicians in decision making.Risk of upper gastrointestinal complication, ischemic stroke, myocardial infarction, and heart failure hospitalization with individual NSAIDs UGIC: upper gastrointestinal complications;